DDInter1588 DDInter1658
Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably. Ribociclib was approved by the U.S. FDA in March, 2017 as Kisqali.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Ribociclib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Mirabegron
Ribociclib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Ribociclib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tadalafil
Ribociclib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ripretinib
Ribociclib {u} may lead to a major life threatening interaction when taken with {v} Enzalutamide
Ribociclib {u} may lead to a major life threatening interaction when taken with {v} Lurbinectedin
Ribociclib may cause a minor interaction that can limit clinical effects when taken with Mirabegron
Ribociclib may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Tadalafil
Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib
Ribociclib may lead to a major life threatening interaction when taken with Enzalutamide
Ribociclib may lead to a major life threatening interaction when taken with Lurbinectedin